# Fudan University Shanghai Cancer Center

Source: https://nuclide.cc/institutions/fuscc/  
Nuclide record `fuscc` (Institution). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Fudan University Shanghai Cancer Center is China's leading breast cancer centre and the site of first-in-human TROP2 PET imaging.

## Summary

Fudan University Shanghai Cancer Center is China's leading breast cancer centre, ranked fifty-fifth in the Newsweek/Statista oncology list, and the site of the first-in-human TROP2 PET imaging study. Shao Zhimin's molecular subtyping of triple-negative breast cancer and the FUTURE umbrella trial built on it, the gallium-68 TROP2 nanobody PET tracer from Shaoli Song, and the highest breast cancer surgical volume in the world are its distinguishing contributions, with Yi-Zhou Jiang, Xichun Hu and Dingwei Ye also listed. Nuclide links it to triple-negative breast cancer, to TROP2 as a target and TROP2 PET as a technology, and to Zhongshan Hospital and the Chinese Society of Clinical Oncology. Whether subtype-directed treatment of TNBC improves on a single standard is the question FUTURE was designed to answer. Its TNBC, TROP2 PET and surgery programmes are listed below.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Shanghai, CN
- Type: cancer-center
- Website: https://www.shca.org.cn

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Shanghai_Cancer_Center
- Official website: https://www.shca.org.cn
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- isotopes: [Gallium-68](https://nuclide.cc/isotopes/ga-68/)
- technologies: [TROP2 PET](https://nuclide.cc/technologies/trop2-pet/)
- targets: [TROP2](https://nuclide.cc/targets/trop2/)
- people: [Shaoli Song](https://nuclide.cc/people/song-shaoli/)

---
JSON: https://nuclide.cc/api/v1/entities/fuscc.json